Abstract 70P
Background
NSCLC treatment has evolved after approval of the 1st immunotherapy agent (IO) in 2015. The real-world LIST study of nivolumab for advanced NSCLC aims to describe patient/treatment characteristics, effectiveness, safety and rechallenge outcomes.
Methods
LIST is an ongoing longitudinal, prospective, observational study in patients (pts) with advanced NSCLC receiving nivolumab after one prior chemotherapy-based treatment alone or in combination with IO. Patient cohorts were: Cohort 1, IO-naïve patients; Cohort 2, IO-experienced patients who discontinued for non-IO-toxicity reasons; Cohort 3, IO-experienced patients who discontinued due to IO-toxicity. Descriptive interim analyses (follow-up ≥6 months) are presented.
Results
428 pts were enrolled between Sept 2020 and May 2022 at 99 centres – 278, 128 and 22 pts in cohorts 1, 2 and 3. Baseline patient characteristics were representative of advanced NSCLC: median age 65–70 years, male sex >65%, current/former smoker 22–27%/65–73%, non-squamous histology 60–75%. 41%/ 71%/ 76% of pts in cohorts 1/2/3 had PD-L1 expression (≥1%). At 6 months, respective overall survival (OS) rates were 70.0% [95% confidence interval 64.2–75.1%]/ 61.1% [51.6–69.3%]/ 61.2% [37.1–78.4%] and progression-free survival (PFS) were 33.4% [27.6–39.2%]/ 25.1% [17.2–33.8%]/ 51.0% [28.1–70.0%]. Current/former smokers and pts with tumour PD-L1 expression seem to have improved outcomes (table). All adverse events (AEs) occurred in 86%/ 78%/ 73% of pts and treatment-related grade 3/4 AEs in 11%/ 5%/ 18%, in cohorts 1/ 2/ 3. Table: 70P
Interim survival data by cohort and smoking and PD-L1 status
Cohort 1 (n=278) | Cohort 2 (n=127) | Cohort 3 (n=22) | ||||
Median, months | Rate at 6 months, % | Median, months | Rate at 6 months, % | Median, months | Rate at 6 months, % | |
OS | ||||||
Overall | 12.2 | 70.0 | 8.3 | 61.1 | 10.4 | 61.2 |
Never smoker | 8.1 | 62.9 | 9.5 | 77.8 | – | – |
Former smoker | 12.2 | 72.4 | 6.7 | 54.6 | 10.4 | 58.7 |
Current smoker | 12.6 | 66.5 | 11.0 | 76.0 | – | – |
PD-L1 <1% | – | – | – | – | – | – |
PD-L1 1–49% | 12.2 | 63.6 | 6.7 | 53.5 | – | – |
PD-L1 ≥50% | 7.3 | 61.1 | 9.6 | 60.7 | – | – |
PFS | ||||||
Overall | 3.2 | 33.4 | 2.9 | 25.1 | 7.6 | 51.0 |
Never smoker | 3.0 | 24.0 | – | – | - | - |
Former smoker | 3.9 | 35.6 | 2.2 | 20.6 | 3.2 | 46.7 |
Current smoker | 2.7 | 30.9 | 3.9 | 36.6 | – | – |
PD-L1 <1% | – | – | – | – | – | – |
PD-L1 1–49% | 3.5 | 42.3 | 2.2 | 16.0 | – | – |
PD-L1 ≥50% | 1.8 | 16.7 | 2.1 | 24.8 | – | – |
– = n<15 |
Conclusions
LIST interim results show nivolumab for IO-naïve pts in clinical practice has similar activity and safety as in the registrational CheckMate 017/057 trials. It shows encouraging results of rechallenge with nivolumab in pts with previous IO discontinuation, including for IO-toxicity.
Clinical trial identification
NCT04500535.
Editorial acknowledgement
We thank Sheridan Henness who provided medical writing assistance prior to submission on behalf of Springer Healthcare Communications.
Legal entity responsible for the study
The authors.
Funding
Bristol Myers Squibb.
Disclosure
B. Godbert: Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, AstraZeneca, Sanofi, MSD; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, AstraZeneca, MSD, Sanofi; Financial Interests, Personal, Expert Testimony: Bristol Myers Squibb, AstraZeneca, Sanofi, MSD. M. Zysman: Financial Interests, Institutional, Other: AVAD; Financial Interests, Personal, Speaker, Consultant, Advisor: CSL Behring, GSK, Boehringer Ingelheim, AstraZeneca, Chiesi, Sanofi; Financial Interests, Personal, Other: Chiesi, AstraZeneca, GSK. E. Gobbini: Financial Interests, Institutional, Other: BMS; Financial Interests, Personal, Other: AstraZeneca, Roche, Pfizer, Merck Sharpe and Dohm, Bristol Myers Squibb, Takeda, Janssen, Sanofi. C. Decroisette: Financial Interests, Personal, Speaker, Consultant, Advisor: MSD, BMS, Takeda, Pfizer, Sanofi, Janssen, AstraZeneca, Amgen; Financial Interests, Personal, Other: Amgen, Janssen, Roche, MSD. H. Lena: Financial Interests, Personal, Speaker, Consultant, Advisor: Roche AstraZeneca, MSD, Novartis, Takeda, BMS, Roche, MSD, Pfizer, Lilly, Amgen; Financial Interests, Personal, Other: BMS, Takeda, Pfizer. D. Moro-Sibilot: Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, MSD, Roche, AstraZeneca; Financial Interests, Personal, Other: Roche, MSD; Financial Interests, Personal, Advisory Board: BMS, Roche, MSD; Financial Interests, Institutional, Other: BMS, Roche, MSD. F. Guisier: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, BMS, MSD, Roche, Sanofi, Janssen, Pfizer, Takeda; Financial Interests, Institutional, Research Grant: Pfizer, Roche, Takeda. S. Couraud: Other, Personal, Advisory Board: Adene; Financial Interests, Personal and Institutional, Advisory Board, Institution Funding: Amgen, BMS, MSD, Novartis, Pfizer, Sanofi; Financial Interests, Personal and Institutional, Advisory Board, Institution Funding, Research Funding: AstraZeneca; Financial Interests, Institutional, Research Funding: BD, Transdiag, Volition; Financial Interests, Institutional, Funding: Celgene, Chugai, Janssen, Laidet, Lilly, Roche, Takeda; Financial Interests, Personal, Speaker, Consultant, Advisor: Health EvenT; Financial Interests, Personal, Advisory Board: MaaT Pharma. A. Caraux: Financial Interests, Personal, Affiliate: Bristol Myers Squibb. D. Reynaud: Financial Interests, Personal Boehringer Ingelheim, Affiliate: Bristol Myers Squibb. F. Breliier: Financial Interests, Personal, Affiliate: Bristol Myers Squibb; Financial Interests, Personal, Stocks or ownership: Bristol Myers Squibb. N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer Ingelheim, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Non-Financial Interests, Personal, Officer, International Thymic malignancy interest group, president: ITMIG; Other, Personal, Other, Family member is an employee: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
190P - Immune-related roles of B7H3 in glioblastoma
Presenter: Arnaud Simonet
Session: Poster Display
191P - Senolytic treatment remodels glioblastoma microenvironment
Presenter: Alexa Saliou
Session: Poster Display
192P - Analysis of Tumor-Associated Macrophages and Tumor-infiltrating Lymphocytes within the Tumor Microenvironment of Primary Tumors and Matched Brain Metastases
Presenter: Markus Kleinberger
Session: Poster Display
193P - Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibit anti-cancer immunity via CCL2
Presenter: Ronja Wieboldt
Session: Poster Display
194P - Achieving Reproducible Maturation Staging of Tertiary Lymphoid Structures: from Imaging Mass Cytometry Data to Pathology Applications
Presenter: Marion Le Rochais
Session: Poster Display
195P - IMMUcan - Toward a better understanding of the tumor microenvironment to inform precision oncology approaches.
Presenter: Marie Morfouace
Session: Poster Display
196P - Local glycan engineering induces systemic antitumor immune reactions via antigen cross-presentation
Presenter: Natalia Rodrigues Mantuano
Session: Poster Display
197P - Computational pathology pipeline enables quantification of intratumor heterogeneity and tumor-infiltrating lymphocyte score
Presenter: Daniel Tiezzi
Session: Poster Display
198P - Polarization of tumor-associated macrophages enhanced by 2-HP-_-cyclodextrin modified PLGA nanoparticles
Presenter: HAO YUAN
Session: Poster Display
199P - Scalable multiplexed image analysis across cancer types as part of the IMMUcan consortium
Presenter: Nils Eling
Session: Poster Display